Filtered By:
Condition: Hypertension
Drug: Coumadin
Education: Study

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Low-Dose Aspirin Linked To Bleeding In The Skull, New Report Says
(CNN) — Taking low-dose aspirin to prevent heart disease and stroke is associated with an increased risk of bleeding in the skull in people without a history of those conditions, according to a new report. Researchers analyzed data from 13 previous studies in which over 130,000 people ages 42 to 74, who didn’t have a history of heart disease or stroke, were given either aspirin or a placebo for the prevention of these conditions. All the trials reported on the risk of head bleeding. People who took the placebo had a 0.46% risk of having a head bleed during the combined trial periods. For those who took aspirin,...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 13, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News aspirin CNN Source Type: news

Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial
ConclusionIn ENSURE-AF, thromboembolic events were rare and absolute bleeding event rates were higher with concomitant APT. These findings may be relevant for AF-patients considered for dual therapy; even for a short treatment duration of 1  month.
Source: Clinical Research in Cardiology - March 30, 2020 Category: Cardiology Source Type: research

Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy.
CONCLUSION: The incidence of GI bleeding was lower in AF patients who received rivaroxaban compared to those treated with warfarin. Also, GI bleeding risk does not change according to the consumption of other anti-coagulant drugs and un-derlying history of hypertension or stroke in patients received rivaroxaban. Therefore, rivaroxaban is suggested as the choice of prophylaxis in patients with AF and concomitant coagulopathy. PMID: 33390152 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - January 5, 2021 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The Risk of Falling and Consequences of Falling in Patients with Atrial Fibrillation Receiving Different Types of Anticoagulant
ConclusionOlder patients who had comorbidities and were taking amiodarone, diuretics, or short- or medium-acting benzodiazepines had the highest risk of falls. The type and quality of anticoagulation did not seem to affect the risk of falling but did significantly affect survival after the first fall.
Source: Drugs and Aging - March 2, 2021 Category: Geriatrics Source Type: research

Effect of Age on Treatment, Trends and Outcome of Patients Hospitalized With Atrial Fibrillation: Insights From a 20-Years Registry in a Middle-eastern Country (1991-2010).
Conclusion: Anticoagulation remains underutilized in elderly patients with AF despite proven efficacy and increasing trends of cardiovascular comorbidities. The current study underscores the urgent need for prospective studies to investigate warfarin contraindications, relative warfarin efficacy and bleeding risks in our region to help guide healthcare providers in warfarin prescribing in this frail patient population and consequently reduce the risk of AF-related disabling strokes and mortality. PMID: 23211770 [PubMed - as supplied by publisher]
Source: Aging Clinical and Experimental Research - November 26, 2012 Category: Geriatrics Authors: Salam AM, Albinali HA, Al-Sulaiti EM, Al-Mulla AW, Singh R, Al Suwaidi J Tags: Aging Clin Exp Res Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries
Source: Annals of Pharmacotherapy Area: Evidence > Medicines Management > References Background: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low.  In 2008, the US Medicare Part D programme was expanded to pay for medications for Medicare enrollees. Objective: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. Methods: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in ...
Source: NeLM - Cardiovascular Medicine - January 24, 2013 Category: Cardiology Source Type: news

Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
Conclusion: These results demonstrate the necessity for improved quality of physician care of patients with AF, especially with regards to antithrombotic therapy. PMID: 23666295 [PubMed - in process]
Source: Turk Kardiyoloji Dernegi arsivi - March 1, 2013 Category: Cardiology Authors: Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, Kahya Eren N, Cağlıyan CE, Köroğlu B, Vatan B, Acar G, Yüksel M, Bilik MZ, Gedik S, Simşek Z, Akıl MA, Yılmaz R, Oylumlu M, Arıbaş A, Yıldız A, Aydın M, Yeter E, Kanadaşı M, Ergene O, Ozha Tags: Turk Kardiyol Dern Ars Source Type: research

Medical management of critical limb ischaemia: where do we stand today?
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - June 26, 2013 Category: Internal Medicine Authors: Matthew A. Lambert, Jill J. F. Belch Tags: Review Source Type: research

Risk of Subarachnoid Hemorrhage and Early Case Fatality Associated With Outpatient Antithrombotic Drug Use Clinical Sciences
Conclusions— Outpatient antithrombotic drug use was associated with an increased risk of SAH, but no association was observed with early case fatality.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Garbe, E., Kreisel, S. H., Behr, S. Tags: Heparin, Coumarins, Platelet function inhibitors, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Clinical Sciences Source Type: research

Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation Results From a Multicenter Prospective Registry
ConclusionsUninterrupted rivaroxaban therapy appears to be as safe and efficacious in preventing bleeding and thromboembolic events in patients undergoing AF ablation as uninterrupted warfarin therapy.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 10, 2014 Category: Cardiology Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation
Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events...
Source: Seminars in Hematology - April 9, 2014 Category: Hematology Authors: Georg Noll, Sarah Noll, David Hürlimann Source Type: research

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
ConclusionsIn this large observational study, the MB rate was generally consistent with the registration trial results, and fatal bleeds were rare.
Source: Clinical Cardiology - December 1, 2014 Category: Cardiology Authors: Sally Tamayo, W. Frank Peacock, Manesh Patel, Nicholas Sicignano, Kathleen P. Hopf, Larry E. Fields, Troy Sarich, Shujian Wu, Daniel Yannicelli, Zhong Yuan Tags: Quality and Outcomes Source Type: research

Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
Conclusions: In this small prospective observational study, patients with NOAC-associated ICH had smaller ICH volumes and better clinical outcomes compared with warfarin-associated ICH.
Source: Neurology - January 25, 2016 Category: Neurology Authors: Wilson, D., Charidimou, A., Shakeshaft, C., Ambler, G., White, M., Cohen, H., Yousry, T., Al-Shahi Salman, R., Lip, G. Y. H., Brown, M. M., Jager, H. R., Werring, D. J., On behalf of the CROMIS-2 collaborators Tags: Prognosis, Clinical trials Observational study (Cohort, Case control), Intracerebral hemorrhage ARTICLE Source Type: research

Arrive: A retrospective registry of Indian patients with venous thromboembolism
Conclusion: Acute DVT alone was responsible for the substantial burden of VTE in Indian patients. Bleeding was not the limiting factor for anticoagulant treatment in most patients.
Source: Indian Journal of Critical Care Medicine - March 8, 2016 Category: Intensive Care Authors: Dhanesh R KamerkarM Joseph JohnSanjay C DesaiLiesel C DsilvaSadhna J Joglekar Source Type: research